The acquisition has closed — MASI shareholders have been cashed out at $180/share. Any remaining shares should be tendered for the merger consideration. Monitor Danaher (DHR) for integration updates and potential synergies in the medical technology segment.
Price Chart
Executive Summary
Danaher Corporation has completed its acquisition of Masimo Corp on June 10, 2026, with Masimo shareholders receiving $180.00 per share in cash, representing a 38% premium to the pre-announcement price. Masimo's common stock ceased trading on Nasdaq and will be deregistered, with the company becoming a wholly owned subsidiary of Danaher. The Merger Agreement's credit facility was terminated and repaid, the board was replaced, and three executives (Catherine Szyman, Gregory Meehan, Charles Dadswell) entered into separation and consulting agreements for a three-month transition period.
Key Facts
- Danaher completed the acquisition of Masimo Corp on June 10, 2026, with Masimo becoming a wholly owned subsidiary of Danaher.
- Masimo shareholders received $180.00 per share in cash, a 38% premium to the pre-announcement stock price.
- Masimo's common stock ceased trading on Nasdaq prior to the market open on the Closing Date and will be deregistered via Form 25 and Form 15.
- Six directors resigned from the Masimo board at the Effective Time; Frank McFaden (director of Merger Sub) became the sole director of the surviving corporation.
- The company terminated and repaid all obligations under its Credit Agreement with Bank of America dated December 1, 2025.
- Catherine Szyman, Gregory Meehan, and Charles Dadswell entered into separation and consulting agreements with a 3-month consulting period post-closing.
- Parent funded the acquisition with cash on hand.
Financial Impact
Danaher acquired Masimo for approximately $9.4 billion, paying $180.00 per share in cash. The premium to pre-announcement price was approx. 38%.
Risk Factors
- Integration risk: combining Masimo's operations with Danaher's existing life sciences portfolio could face execution challenges.
- Regulatory risk: potential antitrust or regulatory conditions attached to the merger could impose operational constraints.
- Key personnel risk: three senior executives (Catherine Szyman, Gregory Meehan, Charles Dadswell) have departed, with only a 3-month consulting transition period.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-072151 |
| Document: tm2617395d1_ex3-2.htm | 0001104659-26-072151 |
| Document: tm2617395d1_8k.htm | 0001104659-26-072151 |
| Document: tm2617395d1_ex3-1.htm | 0001104659-26-072151 |
| Document: 0001104659-26-072151-index-headers.html | 0001104659-26-072151 |
| Document: 0001104659-26-072151-index.html | 0001104659-26-072151 |
| Document: 0001104659-26-072151.txt | 0001104659-26-072151 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 22, 2026 14w ago | 15-12G | — | awaiting T+5 | — | — |
Jun 10, 2026 16w ago | 8-K | $179.95 $179.95 | · 0.00% | ▼ −2.14% | — |
May 4, 2026 21w ago | 8-K | $177.90 $178.08 | ▲ +0.10% | ▼ −2.83% | — |
Apr 21, 2026 23w ago | Court Ruling | $178.21 $178.10 | ▲ +0.06% | ▲ +1.15% | — |
Apr 1, 2026 26w ago | DEFM14A | $177.95 $177.88 | ▼ −0.04% | ▼ −3.80% | — |
Mar 18, 2026 28w ago | PREM14A | $178.51 $176.87 | ▼ −0.92% | ▲ +1.29% | — |
Feb 27, 2026 30w ago | DFAN14A | $175.27 $175.42 | ▲ +0.09% | ▲ +1.29% | — |
Jan 23, 2026 36w ago | Court Ruling | $140.64 $137.02 | ▼ −2.57% | ▼ −2.96% | — |
Jan 23, 2026 36w ago | Court Ruling | $140.64 $137.02 | ▼ −2.57% | ▼ −2.96% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access